HLA-DRB1
Immune System · HLA & Antigen Processing Presentation
Why are HLA-DRB1 results usually written with detailed allele numbers?
HLA-DRB1 has many forms that influence how protein fragments are presented to immune cells. Those distinctions are needed for allele-specific interpretation, so the broad gene label loses clinically relevant detail.
- Common Gene Name
- major histocompatibility complex, class II, DR beta 1
- NCBI Gene ID
- 3123
- Chromosome
- 6
Clinical Evidence Status
Drug-response evidence availableTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (17 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| Crohn disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Idiopathic pulmonary fibrosis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Narcolepsy | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Psoriatic arthritis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Idiopathic inflammatory myopathy | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Juvenile idiopathic arthritis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Type 1 diabetes | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Multiple sclerosis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Hashimoto thyroiditis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Graves disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Rheumatoid arthritis | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Autoimmune Addison disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Alopecia areata | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Lyme disease | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Rosacea | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2025-09 | |
| Lapatinib | FDA pharmacogenetics | Potential safety or response effect | Drug-specific subgroup | View source |
| Lapatinib (4) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Immune System